Korro Bio, Inc.: Venrock Healthcare Capital Partners III, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Venrock Healthcare Capital Partners III, L.P. filed an amended Schedule 13G with the SEC (accession 0001738048-26-000096) updating its beneficial ownership position in Korro Bio, Inc. The filing is a passive-investor disclosure rather than an activist statement, indicating the venture firm's stake remains held for investment purposes. The amendment did not disclose a change in share count in the headline, so the precise size and direction of any position adjustment remain to be confirmed in the full document. Investors should watch for the detailed ownership percentage and any subsequent 13G or Form 4 filings from Venrock for signals on institutional conviction in the RNA-editing developer.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Venrock Healthcare Capital Partners III, L.P., Korro Bio, Inc.